fda indications for semaglutide Clears Cardiac Risk Reduction in Diabetic Patients Oral Semaglutide Gets FDA Approval

Am J Health Syst Pharm 63(5):411418 Brown E, Heerspink HJ, Cuthbertson DJ, Wilding JP (2021) SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

As an end note, the author found GenAI helpful in reviewing this article, but he is not prepared to have it make diagnoses from radiographs or create treatment plans yet

[1] [4] NICE guidance (TA875) specifies that Wegovy should be prescribed within specialist weight management services, typically for a maximum duration of 2 years

Not everyone can tolerate GLP-1s, and for some the medication may not be effective for achieving meaningful weight loss